BrukerBRKR
BRKR
About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Employees: 11,396
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
40% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]
28% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 113
4.06% more ownership
Funds ownership: 76.8% [Q3] → 80.85% (+4.06%) [Q4]
8% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 63
0% more funds holding
Funds holding: 363 [Q3] → 363 (+0) [Q4]
9% less capital invested
Capital invested by funds: $7.93B [Q3] → $7.19B (-$745M) [Q4]
65% less call options, than puts
Call options by funds: $32.8M | Put options by funds: $93M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
38%
upside
Avg. target
$54
50%
upside
High target
$60
65%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Wells Fargo Brandon Couillard 24% 1-year accuracy 6 / 25 met price target | 65%upside $60 | Overweight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target | 38%upside $50 | Overweight Maintained | 10 Apr 2025 |
Citigroup Patrick Donnelly 26% 1-year accuracy 8 / 31 met price target | 38%upside $50 | Buy Maintained | 7 Apr 2025 |
Stifel Daniel Arias 11% 1-year accuracy 2 / 19 met price target | 57%upside $57 | Hold Maintained | 14 Feb 2025 |
Financial journalist opinion
Based on 12 articles about BRKR published over the past 30 days
Neutral
Business Wire
3 days ago
Bruker Introduces nVista 2P Miniature Microscope
SAN JOSE, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innov.
Neutral
Business Wire
4 days ago
Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays. Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gerno.
Positive
Zacks Investment Research
6 days ago
Bruker Stock May Benefit Following Its Investment in Ridom GmbH
BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.
Neutral
Zacks Investment Research
1 week ago
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.
Positive
Benzinga
1 week ago
Why Is Life Science Focused Bruker Stock Trading Higher On Friday?
Bruker Corporation BRKR reported preliminary revenue Friday for the first quarter that ended March 31, 2025, of $795 million to $800 million compared to a consensus of $758.85 million.
Neutral
Business Wire
1 week ago
Bruker Announces First Quarter 2025 Preliminary Revenue
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first.
Neutral
Business Wire
1 week ago
Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing
VIENNA--(BUSINESS WIRE)---- $BRKR #BRKR--At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use only NGS-based solutions in epidemiology and hospital acquired infection (HAI) tracing. Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in.
Positive
Zacks Investment Research
1 week ago
Bruker Announces Groundbreaking 1.3 GHz NMR System, Stock Up
BRKR's new 1.3 GHz high-resolution NMR system comes with a stable, standard-bore 54 mm superconducting magnet.
Neutral
Business Wire
1 week ago
Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System
ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chap.
Neutral
Business Wire
1 week ago
Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR
ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent' configuration. This novel Fourier 80 ‘Multi-Talent' system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs.
Charts implemented using Lightweight Charts™